GetTopicDetailResponse(id=9a4d599340b, topicName=普拉格雷, introduction=普拉格雷, content=null, image=null, comments=1, allHits=2420, url=https://h5.medsci.cn/topic?id=59934, type=1, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=1504, tagList=[TagDto(tagId=1504, tagName=普拉格雷)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=881742, encodeId=623b881e4203, content=在接受PCI的亞洲<a href='/topic/show?id=ab99522007b' target=_blank style='color:#2F92EE;'>#急性冠脈綜合征#</a>患者中，<a href='/topic/show?id=36d313833c9' target=_blank style='color:#2F92EE;'>#PCI#</a>后1個(gè)月以<a href='/topic/show?id=9a4d599340b' target=_blank style='color:#2F92EE;'>#普拉格雷#</a>為基礎(chǔ)的減劑量方案可降低長(zhǎng)達(dá)1年的凈臨床預(yù)后風(fēng)險(xiǎn)，不過，在國(guó)內(nèi)以<a href='/topic/show?id=43666034930' target=_blank style='color:#2F92EE;'>#替格瑞洛#</a>和<a href='/topic/show?id=5a626408e66' target=_blank style='color:#2F92EE;'>#氯吡格雷#</a>為主的方案，看來也需要研究, objectTitle=Lancet：雙重抗血小板療法“減劑量策略”明顯改善急性冠脈綜合征患者PCI術(shù)后預(yù)后, objectType=article, longId=200114, objectId=73b8200114c1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202091/1598928074895_2110107.PNG, objectUrl=/article/show_article.do?id=73b8200114c1, replyNumber=0, likeNumber=422, createdTime=2020-09-01, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73b8200114c1, moduleTitle=Lancet：雙重抗血小板療法“減劑量策略”明顯改善急性冠脈綜合征患者PCI術(shù)后預(yù)后, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=73b8200114c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
